Get startedLog in
    Picture of Akero Therapeutics logo

    AKRO — Akero Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapMomentum Trap
    All News

    Brief: Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program

    Picture of Akero Therapeutics logoAkero Therapeutics
    18/12/2023 12:09
    Dec 18 (Reuters) - Akero Therapeutics Inc  AKRO.O :
    * AKERO THERAPEUTICS ANNOUNCES FIRST PATIENTS DOSED IN
EFRUXIFERMIN PHASE 3 SYNCHRONY PROGRAM
    * AKERO THERAPEUTICS INC - END-OF-PHASE 2 FDA MEETING
SCHEDULED
FOR Q1 OF 2024 TO REVIEW PHASE 3 STUDY

Source text for Eikon:  ID:nGNX7X36WF 
Further company coverage:  AKRO.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Akero Therapeutics

    See all news